Summary
GSK's latest move reaffirms the Indian Pharma story!!! Indian companies with their cost advantage have been eating to emerging markets of Global players for some time. They could not be ignored any more!!! GSK like Pfizer - Aurobindo deal, has in stroke ensured regular supply of cost effective medicines for their highly competitive emerging market segment.
Analysis
With every from Governments, Companies, consumers demanding cost effective healthcare, the Pharma companies cannot ignore these calls anymore.
The cost of Pharma manufacturing, drug development, discovery etc... have gone through the roof in Developed Nations.
In order to have sustainable model, out scouring every activity to cost effective centers is the Buzz word.
Look out for many more deals like these in the near future.
Indian companies with well established Global platform make a good buy before they hit the big time!!!
